Fulgent Genetics (FLGT) Net Cash Flow (2015 - 2026)

Fulgent Genetics has disclosed Net Cash Flow across 12 years of filings, most recently posting $2.8 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 86.32% year-over-year to $2.8 million; the TTM figure through Jun 2026 stood at -$61.8 million (down 370.08% YoY), while the FY2025 annual figure was -$5.1 million, up 88.0% from the prior year.
• Net Cash Flow came in at $2.8 million for Q2 2026 at Fulgent Genetics, up from -$26.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $188.2 million in Q1 2022 to a low of -$213.7 million in Q2 2022.
• Average Net Cash Flow over 5 years is -$7.7 million, with a median of $27000.0 recorded in 2024.
• The largest YoY upside for Net Cash Flow was 519.49% in 2025 against a maximum downside of 2342.95% in 2025.
• Over 5 years, Net Cash Flow stood at -$89.0 million in 2022, then jumped by 114.89% to $13.3 million in 2023, then slumped by 120.86% to -$2.8 million in 2024, then tumbled by 2342.95% to -$67.5 million in 2025, then jumped by 104.17% to $2.8 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $2.8 million in Q2 2026, -$26.8 million in Q1 2026, and -$67.5 million in Q4 2025.